Filing Details
- Accession Number:
- 0000950170-25-075482
- Form Type:
- 13G Filing
- Publication Date:
- 2025-05-19 20:00:00
- Filed By:
- AP11 Limited
- Company:
- Sagimet Biosciences Inc.
- Filing Date:
- 2025-05-20
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
|---|---|---|---|
| AP11 Limited | 0 | 1,654,701 | 5.4% |
| Ascletis Pharma Inc. | 0 | 1,654,701 | 5.4% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Sagimet Biosciences Inc. (Name of Issuer) |
Series A common stock (Title of Class of Securities) |
786700104 (CUSIP Number) |
12/31/2023 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 786700104 |
| 1 | Names of Reporting Persons
AP11 Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
VIRGIN ISLANDS, BRITISH
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,654,701.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
5.4 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO, FI |
Comment for Type of Reporting Person: The reported percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of March 5, 2025, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on March 12, 2025
SCHEDULE 13G
|
| CUSIP No. | 786700104 |
| 1 | Names of Reporting Persons
Ascletis Pharma Inc. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,654,701.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
5.4 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO, FI |
Comment for Type of Reporting Person: The reported percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of March 5, 2025, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on March 12, 2025.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Sagimet Biosciences Inc. | |
| (b) | Address of issuer's principal executive offices:
155 BOVET RD., SUITE 303, SAN MATEO, California, 94402 | |
| Item 2. | ||
| (a) | Name of person filing:
AP11 Limited
Ascletis Pharma Inc. | |
| (b) | Address or principal business office or, if none, residence:
AP11 Limited - 12/F, Building D, No. 198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou China, 311200
Ascletis Pharma Inc. - 12/F, Building D, No. 198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou China, 311200 | |
| (c) | Citizenship:
AP11 Limited - British Virgin Islands
Ascletis Pharma Inc. - Cayman Islands | |
| (d) | Title of class of securities:
Series A common stock | |
| (e) | CUSIP No.:
786700104 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
AP11 Limited - 1,654,701 Ascletis Pharma Inc. - 1,654,701 | |
| (b) | Percent of class:
AP11 Limited - 5.4% Ascletis Pharma Inc. - 5.4% | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
AP11 Limited - 1,654,701 Ascletis Pharma Inc. - 1,654,701 | ||
| (ii) Shared power to vote or to direct the vote:
AP11 Limited - 0 Ascletis Pharma Inc. - 0 | ||
| (iii) Sole power to dispose or to direct the disposition of:
AP11 Limited - 1,654,701 Ascletis Pharma Inc. - 1,654,701 | ||
| (iv) Shared power to dispose or to direct the disposition of:
AP11 Limited - 0 Ascletis Pharma Inc. - 0 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|